Safety study of SMOFlipid for patients needing IV nutrition
Part of Hormones & metabolism clinical trials.
This trial tests if SMOFlipid, a special lipid emulsion given through an IV, is safe for children and adults who need most of their nutrition from IV for at least 8 weeks. It looks for side effects like essential fatty acid deficiency or liver problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 1 month old
- You need IV nutrition (PN) at least 5 days a week
- At the start, you get 80% or more of your energy from IV nutrition, and expect to continue that for at least 56 days
- You cannot have used other IV lipid emulsions besides SMOFlipid in the last 6 months
- You must not have severe liver, kidney, blood, or metabolic problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks if children who need Omegaven for eight weeks or longer develop a lack of essential fats. It is for kids with liver issues caused by IV nutrition who cannot eat or digest food normally.
This study compares the standard peanut-based therapeutic food for treating severe malnutrition in young children with a newly developed, specially formulated therapeutic food that may be even better. If your child qualifies, they may receive one of these high-energy foods to help them gain strength and weight.
This study compares two types of IV nutrition (Intralipid and SMOF Lipid) for children undergoing stem cell transplants for leukemia. It aims to find which option is better for helping them recover.
This study tests a new medicine called OPF-110 to see if it is safe and tolerable in healthy adults. It will help determine if further testing in patients is possible.
This trial compares how well different forms of an experimental drug are absorbed by the body. Healthy volunteers will receive the drug and have blood tests to see which version works best.
This study tests whether RELIZORB helps children with short bowel syndrome (SBS), who rely on IV nutrition (and also tube feeding), absorb fats better. It is an open-label study over 90 days, meaning everyone gets the study treatment and outcomes are compared over time.
Hear when a new Malnutrition, Child trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.